462 related articles for article (PubMed ID: 33839324)
1. Gene therapy for ALS: A review.
Amado DA; Davidson BL
Mol Ther; 2021 Dec; 29(12):3345-3358. PubMed ID: 33839324
[TBL] [Abstract][Full Text] [Related]
2. Approaches to Gene Modulation Therapy for ALS.
Meijboom KE; Brown RH
Neurotherapeutics; 2022 Jul; 19(4):1159-1179. PubMed ID: 36068427
[TBL] [Abstract][Full Text] [Related]
3. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy.
Cappella M; Pradat PF; Querin G; Biferi MG
J Neuromuscul Dis; 2021; 8(1):25-38. PubMed ID: 33074186
[TBL] [Abstract][Full Text] [Related]
4. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
Ly CV; Miller TM
Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotides for the Study and Treatment of ALS.
Boros BD; Schoch KM; Kreple CJ; Miller TM
Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
[TBL] [Abstract][Full Text] [Related]
6. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.
Lagier-Tourenne C; Baughn M; Rigo F; Sun S; Liu P; Li HR; Jiang J; Watt AT; Chun S; Katz M; Qiu J; Sun Y; Ling SC; Zhu Q; Polymenidou M; Drenner K; Artates JW; McAlonis-Downes M; Markmiller S; Hutt KR; Pizzo DP; Cady J; Harms MB; Baloh RH; Vandenberg SR; Yeo GW; Fu XD; Bennett CF; Cleveland DW; Ravits J
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4530-9. PubMed ID: 24170860
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy in Amyotrophic Lateral Sclerosis.
Fang T; Je G; Pacut P; Keyhanian K; Gao J; Ghasemi M
Cells; 2022 Jun; 11(13):. PubMed ID: 35805149
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy for ALS-A Perspective.
Cappella M; Ciotti C; Cohen-Tannoudji M; Biferi MG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500113
[TBL] [Abstract][Full Text] [Related]
9. Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.
Mis MSC; Brajkovic S; Tafuri F; Bresolin N; Comi GP; Corti S
Mol Neurobiol; 2017 Aug; 54(6):4466-4476. PubMed ID: 27349438
[TBL] [Abstract][Full Text] [Related]
10. C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis.
Narain P; Gomes J; Bhatia R; Singh I; Vivekanandan P
Neurobiol Aging; 2017 Aug; 56():211.e9-211.e14. PubMed ID: 28527524
[TBL] [Abstract][Full Text] [Related]
11. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].
Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH
Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors.
Merjane J; Chung R; Patani R; Lisowski L
Med Res Rev; 2023 Jul; 43(4):829-854. PubMed ID: 36786126
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Neurodegeneration Related to
Babić Leko M; Župunski V; Kirincich J; Smilović D; Hortobágyi T; Hof PR; Šimić G
Behav Neurol; 2019; 2019():2909168. PubMed ID: 30774737
[TBL] [Abstract][Full Text] [Related]
14. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels.
Beckers J; Tharkeshwar AK; Van Damme P
Autophagy; 2021 Nov; 17(11):3306-3322. PubMed ID: 33632058
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 levels in the brain tissue of ALS cases with and without
Yang Y; Halliday GM; Kiernan MC; Tan RH
Neurology; 2019 Nov; 93(19):e1748-e1755. PubMed ID: 31619481
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic tools for familial ALS.
Camu W; De La Cruz E; Esselin F
Rev Neurol (Paris); 2023; 179(1-2):49-53. PubMed ID: 36503675
[TBL] [Abstract][Full Text] [Related]
17. Silencing strategies for therapy of SOD1-mediated ALS.
van Zundert B; Brown RH
Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
[TBL] [Abstract][Full Text] [Related]
18. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
19. ALS Genetics: Gains, Losses, and Implications for Future Therapies.
Kim G; Gautier O; Tassoni-Tsuchida E; Ma XR; Gitler AD
Neuron; 2020 Dec; 108(5):822-842. PubMed ID: 32931756
[TBL] [Abstract][Full Text] [Related]
20. Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion.
Sathyaprakash C; Manzano R; Varela MA; Hashimoto Y; Wood MJA; Talbot K; Aoki Y
Methods Mol Biol; 2020; 2176():185-208. PubMed ID: 32865792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
